Treatment Of Giant Congenital Melanocytic Nevi Research Articles

Refinements in the Preexpanded Distant Flap for Giant Melanocytic Nevi of the Upper Extremity in Pediatric Patients.

Surgical treatment of large and giant congenital melanocytic nevi (GCMN) of the upper extremity is challenging because of limited options for reconstruction. A preexpanded distant flap is considered an important option in upper extremity reconstruction, where the soft tissue available for use is limited. The authors aimed to refine the preexpanded distant flap after excision of the GCMN in the upper extremity. Large (>10 cm) and giant (>20 cm) congenital melanocytic nevi of the upper extremities treated with tissue expansion and distant flaps over 10 years were retrospectively reviewed, and the authors describe in detail the surgical strategies for reconstruction of the upper extremity with a distant flap. From March of 2010 to February of 2020, 13 patients (mean age, 2.87 years) treated with 17 preextended distant flaps were included. The mean flap dimension was 154.87 cm 2 , ranging from 15 × 5 to 26.5 × 11 cm. All procedures were successfully completed except for one, in which partial flap necrosis occurred. Preconditioning was performed before flap transfer in 5 patients with larger rotation arcs and flap dimensions. The mean duration of postoperative follow-up was 51.85 months. A new reconstructive protocol was proposed that combined the 3 elements, including a distant flap, tissue expander, and preconditioning. In the treatment of GCMN in the upper extremities, careful planning and multiple stages are required. For pediatric patients, the preextended distant flap with preconditioning is useful and effective for reconstruction. Therapeutic, IV.

Serial Excision for the Treatment of Giant Congenital Melanocytic Nevus: The Vietnamese Way.

AIM:To investigate the efficacy of plastic surgery in the treatment of giant congenital melanocytic nevus (GCMN).METHODS:We enrolled 20 patients with 44 lesions and performed one of the following procedures: serial excision, skin grafting, tissue expansion, primary skin closure, distant flap, and adjacent flap. We assessed the outcome at 10 days and 6 months after surgery.RESULTS:Of 44 surgical sites, the most commonly used reconstruction surgeries were serial excision (16), skin grafting (16), and tissue expansion (6). Other types were rarely used. All patients with serial excision had good outcome. A total of 81% and 19% of the patients with skin grafting had good and fair outcome, respectively. Around 83% and 17% of the patients with tissue expansion had good and fair outcome. No cases had bad outcome.CONCLUSION:In conclusion plastic surgery is effective in the treatment of GCMN. There are different techniques but serial excision, skin grafts, and tissue expansion are most commonly used.

Giant Congenital Melanocytic Nevus (GCMN) - A New Hope for Targeted Therapy?

We present a 6-month-old male patient, who was consulted with dermatologist by his parents, because of a pigmented lesion, present since birth, covering almost the all skin of the back and buttocks. A sharply bordered, unequally coloured congenital pigmented nevus, measuring approximately 21 cm in diameter was observed in the whole body skin examination. The lesion was affecting the lower 2/3 of the skin of the back and the top half of the gluteus area, extending to the lateral part of the tors, forward the abdomen and the upper lateral part of the hips, composed by multiple darker-pigmented nests and several lighter areas, with single depigmented zones, hairy surface, irregularly infiltrated on palpation. Congenital melanocytic nevi are presented in approximately 1% of newborns, while giant congenital melanocytic nevi (GCMN) are the most uncommon subtype of them; with occurrence rate 1 in 50,000 births. They affect 2% of a total body surface or presenting in a diameter larger than 20 cm in older children. Although not common, the possible malignant transformation remains one of the most important considerations related to them, as the related lifetime risk of melanoma is 4% to 10%. Treatment recommendations include non-surgical methods as dermabrasion only within the first two weeks of life, for prevention the possible melanocytic deeper migration, while serial surgical excisions or tissue expanders could be useful treatment tool even in later stages. Nevertheless, cosmetic result is not always satisfactory, and the risk of malignant changes remains, in cases of previous melanocytic migration in deeper layer. Recent article suggests the potential role in the treatment of GCMN with NRAS inhibitor trametinib, approved for treatment of advanced melanoma, associated with underlying NRAS mutations. Although promising, the drug could be useful in paediatric patients, only with associated NRAS gene mutation. It is still unclear whether it could be helpful, independent of the NRAS status.

Giant Congenital Melanocytic Nevus

Giant congenital melanocytic nevi (GCMN) occur in 1:20,000 livebirths and are associated with increased risk of malignant transformation. The treatment of GCMN from 1981 to 2010 in a tertiary referral center was reviewed evaluating the modalities used, cosmetic results, associated complications, and malignant transformation. Of 35 patients, 25 underwent surgery. Curettage was most frequently used (64%) followed by excision and tissue expansion (20%). Six percent of the patients treated with curettage, and 78% of the patients who received excision surgery required more than 1 planned procedure, and 25% versus 44% required unplanned additional surgery, respectively. Complications were noted in 25% and 67% of the patients, respectively. Cosmetic result was satisfying in 76% of patients without difference between the groups. No malignant transformation was found during a mean follow-up of 11 years. Curettage is a gentle alternative to excision with a lower complication rate and good cosmetic outcome.

Hydrosurgery as a new non-excisional treatment method for giant congenital melanocytic nevi

Giant congenital melanocytic nevi (GCMN) are a source of esthetic embarrassment and psychosocial distress but may also be complicated by involvement of the central nervous system and malignant deformation. GCMN treatment remains a point of discussion. We suggest hydrosurgery as a new non-excisional treatment method for GCMN. Hydrosurgery has a lot of advantages in comparison to other non-excisional techniques. We were able to remove the epidermis and upper layer of the dermis of these GCMN in a more precise and controlled manner. The operation time was shorter, there was less blood loss, and shorter anesthesia times. Hydrosurgery is an easier and more controllable alternative to dermabrasion and curettage in the treatment of GCMN. Level of Evidence: Level V, therapeutic study.

Comparative Treatment of Giant Congenital Melanocytic Nevi with Curettage or Er

Background Treatment options for congenital melanocytic nevi (CMN) include complete surgical excision, dermabrasion, curettage, and laser therapy. Fresh cultured epithelial autograft (CEA) after curettage or erbium:yttrium-aluminum-garnet (Er:YAG) ablation presents a novel option in the management of large-sized or giant CMN. Objective The purpose of this study was to evaluate the outcome of CEA after curettage or Er:YAG ablation of CMN and to compare the safety, efficacy, and side-effect profile of CEA with the non-CEA group. Methods Ten patients with CMN were treated with curettage (one patient), Er:YAG ablation (four patients), or both (five patients) followed by CEA, and eight patients were treated with curettage (two patients), Er:YAG ablation (one patient), or both (five patients) without CEA. All 18 patients were evaluated at week 16 after the operation with respect to pigmentation, erythema, hypertrophic scarring, textural change, granulation tissue formation, infection, and healing time. Global Assessment Scale scores were graded before and 16 weeks after the operation by physicians and patients. Results Reduced pigmentation in the treated areas was seen in both groups, but the time to complete healing was significantly shorter in the CEA than in the non-CEA group (p < .05). There was less hypertrophic scar formation and granulation tissue formation and fewer other side effects in the CEA group. Conclusion In view of the favorable outcome of CEA combined with curettage or Er:YAG laser ablation in the treatment of giant CMN, CEA is a safe and effective novel treatment adjunct that accelerates healing, with fewer side effects.

Comparative Treatment of Giant Congenital Melanocytic Nevi with Curettage or Er:YAG Laser Ablation Alone versus with Cultured Epithelial Autografts

Treatment options for congenital melanocytic nevi (CMN) include complete surgical excision, dermabrasion, curettage, and laser therapy. Fresh cultured epithelial autograft (CEA) after curettage or erbium:yttrium-aluminum-garnet (Er:YAG) ablation presents a novel option in the management of large-sized or giant CMN. The purpose of this study was to evaluate the outcome of CEA after curettage or Er:YAG ablation of CMN and to compare the safety, efficacy, and side-effect profile of CEA with the non-CEA group. Ten patients with CMN were treated with curettage (one patient), Er:YAG ablation (four patients), or both (five patients) followed by CEA, and eight patients were treated with curettage (two patients), Er:YAG ablation (one patient), or both (five patients) without CEA. All 18 patients were evaluated at week 16 after the operation with respect to pigmentation, erythema, hypertrophic scarring, textural change, granulation tissue formation, infection, and healing time. Global Assessment Scale scores were graded before and 16 weeks after the operation by physicians and patients. Reduced pigmentation in the treated areas was seen in both groups, but the time to complete healing was significantly shorter in the CEA than in the non-CEA group (p < .05). There was less hypertrophic scar formation and granulation tissue formation and fewer other side effects in the CEA group. In view of the favorable outcome of CEA combined with curettage or Er:YAG laser ablation in the treatment of giant CMN, CEA is a safe and effective novel treatment adjunct that accelerates healing, with fewer side effects.

Is Laser Therapy an Adequate Treatment for Giant Congenital Melanocytic Nevi?

Summary Treatment of congenital and acquired nevi nevocellulares is still controversial because of the possibility of incomplete destruction of deeper situated nevi cells and the possibility of masking a melanoma. Giant congenital melanocytic nevi (GCMN) are rare disfiguring potentially malignant lesions. The approach towards these patients is based on two main considerations: attempt to minimize the risk of malignancy, and obtain an acceptable cosmetic result. Sometimes they are too large to be removed by multiple surgical excision or by use of osmotic expander. The objective of the treatment of giant congenital nevi is to obtain ablation without side effects and aesthetic after-effects. At this time, however, such treatment does not exist. Treatment of GCMN with laser is not an alternative to surgery. Lasers should only be regarded as a treatment option for GCMN that cannot be surgically excised. For the moment laser therapy of GCMN should be restricted to well controlled studies or to individual patients in whom surgical procedure is not possible or where unacceptable scarring would otherwise result. Today ultrashort high energy pulsed CO2 laser and the normal mode ruby laser are the two lasers available. But their results are too unforeseeable, and painful. The combined use of different lasers cannot give us a better solution. In the future new picosecond Q-switched laser can perhaps provide us with another form of treatment, with less pain, and no scars.